cut volum 6 number 11 april 25 1993 health info-com network medic newslett editor david dodel d.m.d . 
10250 north 92nd street suit 210 scottsdal arizona 85258-4599 usa telephon 1 
602 860-1121 fax 1 
602 451-1165 compil copyright 1993 david dodel d.m.d . 
all right reserv . 
licens herebi grant republish electron media fee charg long text copyright notic licens attach intact republish portion portion . 
the health info-com network newslett distribut biweek . 
articl medic natur welcom . 
if articl pleas contact editor inform submit . 
if interest join autom distribut system pleas contact editor . 
e-mail address editor fidonet 111415 anonym ftp vm1.nodak.edu fax deliveri contact editor inform t a b l e o f c o n t e n t s 1 . 
center diseas control prevent mmwr 23 april 1993 rate cesarean deliveri ........................... 
1 
malaria among u. . 
embassi personnel ................................. 
5 fda approv hib vaccin childreninf ..................... 
8 2 . 
dental news workshop explor oral manifest hiv infect ............... 
11 3 . 
food drug administr news fda approv depo provera inject contracept .................. 
14 new rule speed approv drug life-threaten ill ..... 
16 4 . 
articl research promis preventingslow blind retin diseas .. 
18 affluent diet increas risk of heart diseas ........................ 
20 5 . 
general announc public health profession nation cancer institut 23 public patient avail nation cancer institut ... 
30 6 . 
aid news summari aid daili summari april 19 april 23 1993 .................... 
38 7 . 
aid statist worldwid aid statist ............................................ 
48 hicnet medic newslett page volum 6 number 11 april 25 1993 center diseas control prevent mmwr rate cesarean deliveri unit state 1991 sourc mmwr 4215 date apr 23 1993 cesarean deliveri account near 1 
million approxim 4 million annual deliveri unit state sinc 1986 tabl 1 . 
the cesarean rate unit state third highest among 21 report countri exceed brazil puerto rico 1 . 
this report present data cesarean deliveri cdc 's nation hospit discharg survey nhds 1991 compar data previous year . 
data discharg short-stay nonfeder hospit collect annual sinc 1965 nhds conduct cdc 's nation center health statist . 
for 1991 medic demograph inform abstract sampl 274000 inpati discharg 484 particip hospit . 
the 1991 cesarean vagin birth prior cesarean vbac present report base weight nation estim nhds sampl approxim 31000 11 women discharg deliveri . 
the estim number live birth type deliveri calcul appli cesarean rate nhds live birth nation vital registr data . 
therefor estim number cesarean report agre previous publish data base sole nhds 2 . 
state differ analysi signific 95 confid level base two-tail t-test critic valu 1.96 . 
in 1991 23.5 cesarean per 100 deliveri rate 1990 similar rate 1986-1989 tabl 1 . 
the primari cesarean rate i.e . 
number first cesarean per 100 deliveri women previous cesarean 1986-1991 also stabl rang 16.8 17.5 . 
in 1991 cesarean rate south 27.6 signific p0.05 higher rate west 19.8 midwest 21.8 northeast 22.6 . 
rate higher mother age greater equal 30 year younger women proprietari hospit nonprofit govern hospit hospit fewer 300 bed larger hospit deliveri blue crossblu shield privat insur expect sourc payment sourc payment tabl 2 . 
the pattern character primari cesarean deliveri . 
sinc earli 1970s number percentag birth older women increas howev age distribut mother 1991 remain 1986 overal cesarean rate 1991 would 23.3 essenti 23.5 observ . 
base nhds approxim 4111000 live birth 1991 hicnet medic newslett page 1 
volum 6 number 11 april 25 1993 estim 966000 23.5 cesarean deliveri . 
of estim 338000 35.0 birth repeat cesarean 628000 65.0 primari cesarean . 
sinc 1986 approxim 600000 primari cesarean perform annual . 
in 1986 8.5 women previous cesarean deliv vagin compar 24.2 1991 . 
of cesarean 1991 35.0 associ previous cesarean 30.4 dystocia i.e . 
failur labor progress 11.7 breech present 9.2 fetal distress 13.7 specifi complic . 
the averag hospit stay deliveri 1991 2.8 day . 
in comparison hospit stay primari cesarean deliveri 4.5 day repeat cesarean 4.2 day near twice durat vbac deliveri 2.2 day vagin deliveri vbac 2.3 day . 
in 1986 averag hospit stay deliveri 3.2 day primari cesarean 5.2 day repeat cesarean 4.7 day vbac non-vbac vagin deliveri 2.7 2.6 day respect . 
report offic vital health statist system nation center health statist cdc . 
editori note the cesarean rate unit state steadili increas 1965 1986 howev find report indic rate stabl sinc 1986 3 . 
becaus littl evid matern child health status improv time cesarean associ increas risk complic childbirth nation health object year 2000 4 reduc overal cesarean rate 15 fewer per 100 deliveri primari cesarean rate 12 fewer per 100 deliveri object 14.8 . 
postpartum complic includ urinari tract wound infect may account part longer hospit stay cesarean deliveri vagin birth 5 . 
moreov prolong hospit stay cesarean deliveri substanti increas health-car cost . 
for exampl 1991 averag cost cesarean vagin deliveri 7826 4720 respect . 
the addit cost cesarean deliveri includ 611 physician fee 2495 hospit charg 6 . 
if cesarean rate 1991 15 year 2000 object instead 23.5 number cesarean birth would decreas 349000 617000 versus 966000 result save 1 
billion physician fee hospit charg . 
despit steadi increas vbac rate sinc 1986 sever factor may imped progress toward year 2000 nation health object cesarean deliveri . 
for exampl vbac rate substanti reflect number women offer trial labor increas encourag sinc 1982 7 . 
of women offer trial labor 50-70 could deliv vagin 7 level alreadi achiev mani hospit 8 . 
trial labor routin offer 46 hospit survey 1984 recent year hicnet medic newslett page 2 volum 6 number 11 april 25 1993 nation data avail 9 vbac rate accord nhds data 5.7 . 
the year 2000 object specifi vbac rate 35 base women prior cesarean regardless whether trial labor attempt . 
to reach overal cesarean rate goal howev increas vbac rate need combin substanti reduct primari rate . 
one hospit succeed reduc rate cesarean deliveri appli object criteria four common indic cesarean deliveri requir second opinion institut peer-review process 10 . 
other recommend decreas cesarean deliveri rate includ elimin incent physician hospit equal reimburs vagin cesarean deliveri public dissemin physician- hospital-specif cesarean deliveri rate increas public awar differ practic address malpractic concern may import factor maintain high rate cesarean deliveri 4 . 
refer 1 . 
notzon fc . 
intern differ use obstetr intervent . 
jama 1990 2633286-91 . 
2 . 
grave ej nchs . 
1991 summari nation hospit discharg survey . 
hyattsvill maryland us depart health human servic public health servic cdc 1993 . 
advanc data . 
227 . 
3 . 
taffel sm placek pj kosari cl . 
u. . 
cesarean section rate 1990 updat . 
birth 19921921-2 . 
4 . 
public health servic . 
healthi peopl 2000 nation health promot diseas prevent object full report commentari . 
washington dc us depart health human servic public health servic 1991 dhhs public . 
phs91-50212 . 
5 . 
danforth dn . 
cesarean section . 
jama 1985253811-8 . 
6 . 
hospit insur associ america . 
tabl 4.15 cost matern care physician ' fee hospit charg census region base consum price index 1991 . 
in 1992 sourc book health insur data . 
washington dc hospit insur associ america 1992 . 
7 . 
committe obstetr . 
acog committe opinion . 
64 guidelin vagin deliveri previous cesarean birth . 
washington dc american colleg obstetrician gynecologist 1988 . 
hicnet medic newslett page 3 volum 6 number 11 april 25 1993 8 . 
rosen mg dickinson jc . 
vagin birth cesarean meta-analysi indic success . 
obstet gynecol 199076865-9 . 
9 . 
shiono ph fielden jg mcnelli d rhoad gg pears wh . 
recent trend cesarean birth trial labor rate unit state . 
jama 1987257494-7 . 
10 . 
myer sa gleicher n . 
a success program lower cesarean-sect rate . 
n engl j med 19883191511-6 . 
use trade name commerci sourc identif impli endors public health servic u. . 
depart health human servic . 
hicnet medic newslett page 4 volum 6 number 11 april 25 1993 malaria among u. . 
embassi personnel kampala uganda 1992 sourc mmwr 4215 date apr 23 1993 the treatment prevent malaria africa becom challeng complex problem increas drug resist . 
although risk acquir malaria u. . 
citizen depend station oversea general low risk vari substanti unpredict . 
dure may 1992 offic medic servic depart state omsdo cdc notifi increas number malaria case among offici u. . 
personnel station kampala uganda . 
a review health record embassi health unit ehu kampala indic 27 case malaria diagnos offici personnel march june 1992 compar two case period 1991 . 
ehu omsdo cdc conduct investig confirm report malaria case identifi potenti risk factor malaria among u. . 
embassi personnel . 
this report summar result investig . 
malaria blood smear 25 27 report case-pati avail review omsdo cdc . 
a case malaria confirm slide posit plasmodium sp . 
of 25 person 17 slide- confirm malaria . 
a questionnair distribut person serv ehu obtain inform resid activ use malaria chemoprophylaxi use person protect measur i.e . 
use bednet insect repel window door screen wear long sleev pant even . 
of 157 person elig survey 128 82 respond . 
risk malaria associ sex locat resid kampala . 
although risk malaria higher among children age less equal 15 year 632 19 among person greater 15 year 1194 12 differ signific relat risk rr1.6 95 confid interv ci0.6-4.0 . 
eighty-two percent case occur among person live kampala 1-5 year compar live less 1 
year . 
travel outsid kampala area rural set associ increas risk malaria . 
four malaria chemoprophylaxi regimen use person particip survey mefloquin chloroquin proguanil chloroquin alon proguanil alon . 
in addit 23 18 person respond use malaria chemoprophylaxi . 
the risk malaria signific lower among person use either mefloquin chloroquin proguanil 888 9 among person use regimen prophylaxi 937 24 rr0.4 95 ci0.2-0.9 . 
twelv person use prophylaxi report side effect fear possibl side effect reason . 
the risk malaria lower among person report use bednet hicnet medic newslett page 5 volum 6 number 11 april 25 1993 time 227 7 among person sometim rare use bednet 1599 15 rr0.5 95 ci0.1-2.0 . 
the risk malaria also lower among person consist use insect repel even 016 compar rare use repel 17110 15 rr0 upper 95 confid limit1.2 . 
risk malaria associ failur window door screen wear long sleev pant even . 
as result investig ehu staff review personnel need use compli recommend malaria chemoprophylaxi regimen . 
ehu staff also emphas need use person protect measur made plan obtain insecticide-impregn bednet provid window door screen personnel . 
report u. . 
embassi health unit kampala uganda offic medic svcs dept state washington d.c . 
malaria br div parasit diseas nation center infecti diseas cdc . 
editori note in uganda increas malaria among u. . 
personnel attribut poor adher recommend malaria chemoprophylaxi regimen use person protect measur period increas malaria transmiss intensifi chloroquin resist sub-saharan africa . 
the find report underscor need provid initi continu counsel regard malaria prevent person live abroad malaria-endem area prevent measur also import short-term travel area . 
mefloquin effect prophylaxi regimen africa area chloroquine-resist p . 
falciparum howev area e.g . 
thailand resist mefloquin may limit effect . 
in africa efficaci mefloquin compar chloroquin alon prevent infect p . 
falciparum 92 1 
mefloquin safe well toler given 250 mg per week 2-year period . 
the risk serious advers reaction possibl associ mefloquin prophylaxi e.g . 
psychosi convuls low i.e . 
1.3-1.9 episod per 100000 user 2 risk less sever advers reaction e.g . 
dizzi gastrointestin complaint sleep disturb similar antimalari chemoprophylact 1 . 
doxycyclin similar prophylact efficaci mefloquin need daili dose may reduc complianc effect regimen 34 . 
chloroquin alon effect prophylaxi area intens chloroquin resist e.g . 
southeast asia africa . 
in africa person take mefloquin doxycyclin chloroquin proguanil altern although less effect regimen . 
chloroquin use malaria prevent area chloroquine-resist p . 
falciparum report . 
country-specif recommend prevent malaria inform hicnet medic newslett page 6 volum 6 number 11 april 25 1993 dosag precaut malaria chemoprophylaxi regimen avail health inform intern travel 1992 i.e . 
yellow book 5 24 hour day telephon fax 404 332-4555 . 
refer 1 . 
lobel ho miani m eng t et al . 
long-term malaria prophylaxi week mefloquin peac corp volunt effect well toler regimen . 
lancet 1993341848-51 . 
2 . 
world health organ . 
review central nervous system advers event relat antimalari drug mefloquin 1985-1990 . 
geneva world health organ 1991 public . 
whomal91.1063 . 
3 . 
pang l limsomwong n singharaj p . 
prophylact treatment vivax falciparum malaria low-dos doxycyclin . 
j infect dis 19881581124-7 . 
4 . 
pang l limsomwong n boudreau ef singharaj p . 
doxycyclin prophylaxi falciparum malaria . 
lancet 198711161-4 . 
5 . 
cdc . 
health inform intern travel 1992 . 
atlanta us depart health human servic public health servic 199298 dhhs public . 
cdc92-8280 . 
hicnet medic newslett page 7 volum 6 number 11 april 25 1993 fda approv use new haemophilus b conjug vaccin combin diphtheria-tetanus-pertussi haemophilus b conjug vaccin infant children sourc mmwr 4215 date apr 23 1993 haemophilus influenza type b hib conjug vaccin recommend use infant sinc 1990 routin use infant vaccin contribut substanti declin incid hib diseas unit state 1-3 . 
vaccin diphtheria tetanus pertussi infanc childhood administ routin unit state sinc late 1940s associ greater 90 reduct morbid mortal associ infect organ . 
becaus increas number vaccin routin recommend infant high prioriti develop combin vaccin allow simultan administr fewer separ inject . 
the food drug administr fda recent licens two new product vaccin children diseas 1 
haemophilus b conjug vaccin tetanus toxoid conjug acthib trademark vaccin hib diseas 2 combin diphtheria tetanus toxoid whole-cel pertussi vaccin dtp hib conjug vaccin tetramun trademark combin vaccin formul use vaccin children diphtheria tetanus pertussi hib diseas . 
acthib trademark on march 30 1993 fda approv new haemophilus b conjug vaccin polyribosylribitol phosphate-tetanus toxoid conjug prp-t manufactur pasteur merieux serum et vaccin distribut acthib trademark connaught laboratori inc . 
swiftwat pennsylvania . 
this vaccin licens use infant three-dos primari vaccin seri administ age 2 4 6 month . 
previous unvaccin infant 7-11 month age receiv two dose 2 month apart . 
previous unvaccin children 12-14 month age receiv one dose . 
a booster dose administ 15 month age recommend children . 
previous unvaccin children 15-59 month age receiv singl dose requir booster . 
more 90 infant receiv primari vaccin seri acthib trademark consecut dose 2 4 6 month age develop geometr mean titer anti-haemophilus b polysaccharid antibodi greater 1 
ugml 4 . 
this respons similar infant receiv recommend seri previous licens haemophilus b conjug vaccin efficaci demonstr prospect trial . 
two u. . 
efficaci trial prp-t termin earli concomit licensur haemophilus b conjug vaccin hicnet medic newslett page 8 volum 6 number 11 april 25 1993 use infant 4 . 
in studi case invas hib diseas detect approxim 6000 infant vaccin prp-t . 
these studi suggest efficaci prp-t vaccin similar licens hib vaccin . 
tetramun trademark on march 30 1993 fda approv combin diphtheria tetanus toxoid whole-cel pertussi vaccin dtp haemophilus b conjug vaccin . 
tetramun trademark avail lederle-praxi biolog pearl river new york combin two previous licens product dtp triimmunol regist manufactur lederl laboratori pearl river new york haemophilus b conjug vaccin hibtit regist manufactur praxi biolog inc . 
rochest new york . 
this vaccin licens use children age 2 months-5 year protect diphtheria tetanus pertussi hib diseas indic vaccin dtp vaccin haemophilus b conjug vaccin coincid . 
base demonstr co mparabl higher antibodi respons compon two vaccin tetramun trademark expect provid protect hib well diphtheria tetanus pertussi equival alreadi licens formul dtp haemophilus b vaccin . 
the advisori committe immun practic acip recommend infant receiv primari seri one licens haemophilus b conjug vaccin begin 2 month age booster dose age 12- 15 month 5 . 
the acip also recommend infant receiv four-dos primari seri diphtheria tetanus toxoid pertussi vaccin 2 4 6 15-18 month age booster dose 4-6 year 6-8 . 
a complet statement regard recommend use acthib trademark tetramun trademark develop . 
report offic vaccin research review center biolog evalu research food drug administr . 
div immun nation center prevent svcs mening special pathogen br div bacteri mycot diseas nation center infecti diseas cdc . 
refer 1 . 
adam wg deaver ka cochi sl et al . 
declin childhood haemophilus influenza type b hib diseas hib vaccin era . 
jama 1993269221-6 . 
2 . 
broadhurst le erickson rl kelley pw . 
decreas invas haemophilus influenza diseas u. . 
armi children 1984 1991 . 
jama 1993269227-31 . 
3 . 
murphi tv white ke pastor p et al . 
declin incid haemophilus influenza type b diseas sinc introduct vaccin . 
jama hicnet medic newslett page 9 volum 6 number 11 april 25 1993 1993269246-8 . 
4 . 
fritzel b plotkin s . 
efficaci safeti haemophilus influenza type b capsular polysaccharide-tetanus protein conjug vaccin . 
j pediatr 1992121355-62 . 
5 . 
acip . 
haemophilus b conjug vaccin prevent haemophilus influenza type b diseas among infant children two month age older recommend immun practic advisori committe acip . 
mmwr 199140no . 
rr-1 . 
6 . 
acip . 
diphtheria tetanus pertussi recommend vaccin use prevent measur recommend immun practic advisori committe acip . 
mmwr 199140no . 
rr-10 . 
7 . 
acip . 
pertussi vaccin acellular pertussi vaccin reinforc booster use supplementari acip statement recommend immun practic advisori committe acip . 
mmwr 199241no . 
rr-1 . 
8 . 
acip . 
pertussi vaccin acellular pertussi vaccin fourth fifth dose dtp seri updat supplementari acip statement recommend immun practic advisori committe acip . 
mmwr 199241no . 
rr-15 . 
use trade name commerci sourc identif impli endors public health servic u. . 
depart health human servic . 
hicnet medic newslett page 10 volum 6 number 11 april 25 1993 dental news intern workshop explor oral manifest hiv infect nidr research digest written jodi dove march 1993 nation institut dental research at second intern workshop oral manifest hiv infect held januari 31-februari 3 san francisco particip explor issu relat epidemiolog basic molecular virolog mucos immunolog oral clinic present hiv infect . 
the workshop organ dr . 
john greenspan dr . 
deborah greenspan depart stomatolog school dentistri univers california san francisco . 
an intern steer committe scientif program committe provid guidanc . 
the confer drew 260 scientist 39 countri includ asia africa europ central america south america well unit state canada . 
support tor workshop provid nation institut dental research nation cancer institut nation institut allergi infecti diseas nih offic aid research procter gambl compani . 
among topic discuss epidemiolog hiv lesion ethic profession respons public polici occup issu provis oral care hiv-posit popul salivari hiv transmiss mucos immun opportunist infect pediatr hiv infect women 's issu . 
recommend recommend emerg workshop defin associ appear oral lesion rate progress hiv establish univers terminolog hiv-associ oral lesion look effect treatment oral manifest expand molecular biolog studi understand relationship hiv infect common oral lesion studi effect hiv therapi oral lesion . 
epidemiolog sinc first intern workshop oral manifest hiv infect conven five year ago epidemiolog hiv infect hicnet medic newslett page 11 volum 6 number 11 april 25 1993 radic chang . 
in 1988 hiv infect detect report larg homosexu bisexu male intraven drug user hemophiliac . 
today hiv infect seen heterosexu male femal children adolesc . 
while predomin impact hiv infect felt africa major increas infect rate seen southeast asia well . 
five hundr thousand case report date region appear time . 
research continu document epidemiolog oral lesion hairi leukoplakia candidiasi . 
they also begin explor relationship specif oral lesion hiv diseas progress prognosi . 
socialpolit issu discuss social polit implic hiv infect focus chang public 's attitud aid retribut indiscrimin sexual behavior drug use . 
speaker also address health care deliveri hiv-infect patient need educ public aid acquir . 
saliva salivari gland confer speaker describ transmiss issu hiv-inhibitori activ saliva strength vari among differ salivari secret . 
whole saliva greater inhibitori effect submandibular secret turn greater inhibitori effect parotid secret . 
research shown least two mechan respons salivari inhibitori activ . 
they attribut hiv-inhibitori effect saliva 1 
aggregationagglutin hiv saliva may promot clearanc virus prevent reach target cell 2 direct effect virus target cell . 
other topic discuss manifest salivari gland diseas hiv-infect person current research oral mucos immun . 
pediatr issu pediatr aid recent emerg area intens interest . 
with earli accur diagnosi proper treatment life expect hiv- infect children tripl . 
the prevent transmiss hiv mother child may possibl mani case particular mother 's sero-status known prior give birth . 
periodont gingiv tissu diseas hicnet medic newslett page 12 volum 6 number 11 april 25 1993 oral health research continu explor periodont diseas gingiv found individu hiv infect . 
recommend made workshop includ standard terminolog refin diagnost marker standard studi design proper consider confound variabl result periodont therapi . 
occup treatment issu occup issu surround treatment hiv-infect individu treatment render hiv-infect health care profession still command consider attent . 
factor consider includ costbenefit hiv test patient-to-health care provid transmiss hiv infect revers use mainstream versus dedic facil treatment hiv-infect patient . 
confer particip anticip third intern workshop oral manifest hiv infect held five year less . 
proceed second workshop publish quintess compani late 1993 . 
end part 1 
